Amgen Partners with U.S. Government to Make Medication Affordable for Patients
Amgen, a leader in biopharmaceutical innovation, has recently announced a new initiative in collaboration with the U.S. government aimed at reducing the cost of medications for American patients. This initiative underscores Amgen's long-standing dedication to investing in innovation and U.S. manufacturing. As part of this plan, Amgen is expanding its direct-to-patient program, AmgenNow™, which will now include widely used medications like Aimovig® (erenumab-aooe) and Amjevita® (adalimumab-atto). Both of these medications will be available at an attractive monthly price of $299, marking a significant reduction of nearly 60% and 80%, respectively, from their current U.S. list prices.
The initiative finalized by Amgen is in response to a request outlined in a letter from President Trump, which calls for the U.S. administration's Most Favored Nation pricing requests. Speaking on the matter, Robert A. Bradway, Amgen's chairman and CEO, highlighted the importance of U.S. leadership in biopharmaceutical innovation, expressing hopes for continued collaborative efforts with the government to support innovation on a global scale.
Adding to the impact of these measures is Amgen's commitment to quality manufacturing and research. The company has invested a remarkable $40 billion since 2018 in research and development as well as manufacturing capabilities, enabling them to stay at the forefront of biopharmaceutical advancements. This growth has been aided by beneficial tax reforms, particularly the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025, that have facilitated domestic investments.
Recent expansions have also seen Amgen commit an additional $2.5 billion towards U.S. manufacturing, focusing on expansions in states like Ohio and North Carolina. As a result of these persistent investments in U.S. operations, the company will receive relief from specific industry tariffs for the next three years, further enhancing their ability to serve American patients effectively.
Amgen's dedication is not only reflected in its innovative therapies but also in its substantial contribution to the healthcare environment. Their programs opened through AmgenNow™ aim to make life-saving medications accessible to a broader range of patients, including those uninsured or those enrolled in high-deductible health plans. Such initiatives underscore the core values of Amgen – bringing innovative medicines to those in need at a price point that is workable for the average American.
The significance of Amgen's actions is recognized as it continues to be a part of the Dow Jones Industrial Average and the Nasdaq-100 Index, affirming the company’s stature as one of the most innovative and essential players in the biotechnology sector. Their strong market presence allows them to maintain a robust pipeline of medications that address major health concerns such as cancer, heart disease, osteoporosis, and rare diseases.
As we look to the future, the partnership between Amgen and the U.S. government sets an example for how biopharmaceutical companies can work alongside regulatory bodies to ensure that patient health remains central to policy discussions. With the current initiative, and ongoing investment in domestic production capabilities, the potential for improved access to vital medications continues to grow, paving the way for a healthier future for all Americans. The actions of companies like Amgen serve as crucial stepping stones in the ongoing conversation about healthcare affordability, innovation, and the role of government in supporting the pharmaceutical industry. For more information about Amgen and their commitment to innovation, visit Amgen.com or follow them on their various social media platforms.
The initiative finalized by Amgen is in response to a request outlined in a letter from President Trump, which calls for the U.S. administration's Most Favored Nation pricing requests. Speaking on the matter, Robert A. Bradway, Amgen's chairman and CEO, highlighted the importance of U.S. leadership in biopharmaceutical innovation, expressing hopes for continued collaborative efforts with the government to support innovation on a global scale.
Adding to the impact of these measures is Amgen's commitment to quality manufacturing and research. The company has invested a remarkable $40 billion since 2018 in research and development as well as manufacturing capabilities, enabling them to stay at the forefront of biopharmaceutical advancements. This growth has been aided by beneficial tax reforms, particularly the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025, that have facilitated domestic investments.
Recent expansions have also seen Amgen commit an additional $2.5 billion towards U.S. manufacturing, focusing on expansions in states like Ohio and North Carolina. As a result of these persistent investments in U.S. operations, the company will receive relief from specific industry tariffs for the next three years, further enhancing their ability to serve American patients effectively.
Amgen's dedication is not only reflected in its innovative therapies but also in its substantial contribution to the healthcare environment. Their programs opened through AmgenNow™ aim to make life-saving medications accessible to a broader range of patients, including those uninsured or those enrolled in high-deductible health plans. Such initiatives underscore the core values of Amgen – bringing innovative medicines to those in need at a price point that is workable for the average American.
The significance of Amgen's actions is recognized as it continues to be a part of the Dow Jones Industrial Average and the Nasdaq-100 Index, affirming the company’s stature as one of the most innovative and essential players in the biotechnology sector. Their strong market presence allows them to maintain a robust pipeline of medications that address major health concerns such as cancer, heart disease, osteoporosis, and rare diseases.
As we look to the future, the partnership between Amgen and the U.S. government sets an example for how biopharmaceutical companies can work alongside regulatory bodies to ensure that patient health remains central to policy discussions. With the current initiative, and ongoing investment in domestic production capabilities, the potential for improved access to vital medications continues to grow, paving the way for a healthier future for all Americans. The actions of companies like Amgen serve as crucial stepping stones in the ongoing conversation about healthcare affordability, innovation, and the role of government in supporting the pharmaceutical industry. For more information about Amgen and their commitment to innovation, visit Amgen.com or follow them on their various social media platforms.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.